nexalin technology is a non-invasive and drug-free therapy for those living with anxiety, depression and/or insomnia. nexalin’s patented waveform (1 u.s. patent #6904322b2) the nexalin device produces a patented waveform that provides transcranial electrical stimulation (tes). in clinical trials, this unique waveform resulted in the greatest increase in beta-endorphins. the nexalin device has undergone extensive safety analysis with the results clearly indicating that the device is safe for its intended use. additionally, the fda classification of the device for clinical trials places it into a non-significant risk (low risk device) category. natural frequency will promote balance in the brain by normalizing neurochemistry.this effectiveness of this unique therapy is long lasting and fda approved. laboratory and clinical evidence suggest that nexalin’s patented electrical stimulation affects the hypothalamus and related brain structures to adapt and change the levels of neurochemicals
Company profile
Ticker
NXL
Exchange
CEO
Peter Sohn
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Outset Medical ...
SEC CIK
IRS number
275566468
NXL stock data
Latest filings (excl ownership)
S-3
Shelf registration
15 Apr 24
8-K
Reports on growing clinical data supporting its neurostimulation technology and progress advancing its new Gen-3 HALO™ Clarity Virtual Clinic model
11 Apr 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
20 Mar 24
DEF 14A
Definitive proxy
16 Jan 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Nov 23
DEF 14A
Definitive proxy
5 Oct 23
8-K
Departure of Directors or Certain Officers
28 Sep 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 361.40 k | 361.40 k | 361.40 k | 361.40 k | 361.40 k | 361.40 k |
Cash burn (monthly) | (no burn) | 625.22 k | 805.18 k | 399.29 k | 754.72 k | 366.05 k |
Cash used (since last report) | n/a | 4.17 mm | 5.37 mm | 2.66 mm | 5.04 mm | 2.44 mm |
Cash remaining | n/a | -3.81 mm | -5.01 mm | -2.30 mm | -4.67 mm | -2.08 mm |
Runway (months of cash) | n/a | -6.1 | -6.2 | -5.8 | -6.2 | -5.7 |
Institutional ownership, Q2 2023
10.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 10 |
Opened positions | 7 |
Closed positions | 3 |
Increased positions | 0 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 94.44 mm |
Total shares | 765.82 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 325.00 k | $35.75 mm |
Warberg Asset Management | 166.48 k | $18.31 mm |
Altium Capital Management | 105.00 k | $11.55 mm |
Clear Street | 89.75 k | $10.00 k |
Walleye Capital | 39.04 k | $4.30 mm |
Citadel Advisors | 14.72 k | $1.45 mm |
Boothbay Fund Management | 13.50 k | $12.06 mm |
Tower Research Capital | 9.06 k | $8.10 mm |
UBS UBS Group AG - Registered Shares | 2.00 k | $1.79 mm |
MS Morgan Stanley | 1.26 k | $1.13 mm |
News
12 Health Care Stocks Moving In Friday's Pre-Market Session
19 Apr 24
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
16 Apr 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
16 Apr 24
Nexalin Technology CEO Provides Letter to Shareholders
10 Apr 24
12 Health Care Stocks Moving In Monday's After-Market Session
8 Apr 24
Press releases
Nexalin Technology CEO Provides Letter to Shareholders
10 Apr 24
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
9 Apr 24
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
4 Apr 24
Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device
4 Apr 24
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
28 Mar 24